Kurma Partners — 2024 Investments

2 investments dated 2024 · listed companies and verified rows first · show all

Memo Therapeuticsmemo-therapeutics.com inMay 2024acquired by Clementia

Memo Therapeutics AG is a late-stage biotech company developing therapeutic antibodies for patients with viral infections and cancer.

BiotechMedical Devices

Co-investorsAdjuvant Capital Fresenius Medical Care Ventures Pureos Bioventures Verve Ventures Ysios Capital redalpine

Vico Therapeuticsvicotx.comJan 2024

Vico Therapeutics is a genetic medicine company developing antisense oligonucleotide (ASO) therapies that target the CAG repeat expansion mutation underlying polyglutamine diseases such as Huntington's disease and spinocerebellar ataxias.

AI & Machine LearningBiotechHealthtech

Co-investorsDroia Ventures Pureos Bioventures Seroba Life Sciences EQT Life Sciences Eurazeo Idinvest Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.